复合益生菌对炎症性肠病的治疗及对粪便FNP和FCP蛋白的影响

Effects of compound microecological agents on the treatment of inflammatory bowel disease and on fecal proteins FNP and FCP

目的探究复合益生菌对炎症性肠病(IBD)的治疗及对患者粪便新喋呤(FNP)、钙卫蛋白(FCP)水平的影响。方法选择2017年1月至2018年1月于我院接受治疗的98例IBD患者为试验组,按照随机数字表法将其分为试验组A和试验组B,每组49例患者;另选同期我院结肠镜检查正常的50例健康体检者为对照组。试验组B患者接受常规治疗,试验组A患者在试验组B基础上加用复合益生菌进行治疗,两组患者均治疗8周。比较两组患者治疗有效率,治疗前后的疾病活动指数评分(DAI)、生活质量评分(IBDQ),治疗前后粪便FNP、FCP蛋白水平以及FNP、FCP蛋白水平与IBD患者DAI评分的相关性。结果 (1)试验组A患者治疗有效率为93.88%(46/49),试验组B为79.59%(39/49),差异有统计学意义(P<0.05)。(2)治疗前试验组A及试验组B患者DAI及IBDQ评分差异不具有统计学意义(均P>0.05);治疗后两组患者DAI评分下降、IBDQ评分上升,与治疗前相比差异有统计学意义(均P<0.05),同时试验组A患者DAI评分低于试验组B,IBDQ高于试验组B(均P<0.05)。(3)治疗前试验组患者粪便FNP及FCP水平明显高于对照组(均P<0.05),同时试验组A及试验组B患者粪便FNP、FCP水平对比差异不具有统计学意义(均P>0.05);治疗后试验组A患者粪便FNP及FCP水平均低于试验组B(均P<0.05)。(4)FNP、FCP与IBD患者DAI评分的相关系数分别为0.731和0.762(均P<0.05);结论复合益生菌能够显著缓解IBD患者临床症状,提高患者生活质量,降低其炎症因子水平,同时FNP及FCP与IBD患者疾病活动性具有一定相关性,可作为评估IBD患者疾病状态的指标。

Objective To explore the effects of compound microecological agents on the treatment of inflammatory bowel disease(IBD) and on fecal proteins FNP and FCP. Methods A total of 98 patients with IBD treated in our hospital from January 2017 to January 2018 were selected as Observation group, and randomly divided into observation group A or observation group B with 49 patients in each group. Another 50 patients with normal colonoscopy were selected as control group. Patients in group B received conventional treatment, patients in group A were treated with probiotics combined with conventional treatment. Both groups were treated for 8 weeks. The efficiency rate of treatment, disease activity index(DAI) score, quality of life score(IBDQ), and levels of FNP and FCP before and after the intervention were compared between the two groups. The levels of fecal FNP and FCP and the correlation between levels of FNP and FCP and DAI score of IBD patients were analyzed. Results(1) The efficiency rate was 93.88%(46/49) in group A, and 79.59%(39/49) in group B with significant difference(P<0.05).(2) There were no significant differences in DAI and IBDQ scores between observation group A and group B before treatment(all P>0.05). After treatment, DAI score decreased and IBDQ score increased in both groups, significantly different from those before treatment(all P<0.05);the DAI score was lower(P<0.05), while IBDQ was higher in group A than those in group B(P<0.05) respectively.(3) Before treatment, the levels of FNP and FCP in observation group were significantly higher than those in control group(all P<0.05), and there were no significant differences in levels of FNP and FCP between group A and group B(all P>0.0). After intervention, the levels of FNP and FCP in group A were lower than those in group B(all P<0.05).(4) The correlation coefficients between FNP and FCP and DAI score of IBD patients were 0.731 and 0.762 respectively(all P<0.05). Conclusion The compound probiotics can significantly relieve clinical symptoms, improve the quality of life and reduce the levels of inflammatory factors in patients with IBD. Meanwhile, FNP and FCP have some correlation with the disease activity of IBD patients, which can be used as disease status indicators in patients with IBD.